特征 |
LineZolid疗法组 |
Control group |
全部的 |
受试者n |
33 |
32 |
65 |
Age years |
44 (18–64) |
43(18-63) |
44 (18–64) |
Male sex |
22 (66.7) |
21 (65.6) |
43(66.2) |
体重指数kg·m−2 |
19.5(12–30) |
19.6(12–30) |
19.5(12–30) |
With comorbidity |
|
|
|
Diabetes |
6(18.2) |
6 (18.8) |
12 (18.5) |
Chronic obstructive pulmonary disease |
3(9.1) |
4(12.5) |
7(10.8) |
Bronchiectasis |
8(24.2) |
9 (28.1) |
17 (26.2) |
Tuberculous pleurisy |
6(18.2) |
5 (15.6) |
11 (16.9) |
Respiratory failure¶ |
7 (21.2) |
6 (18.8) |
13(20) |
Decreased albumin |
10(30.3) |
9 (28.1) |
19(29.2) |
Lung cavities |
|
|
|
Unilateral |
16(48.5) |
15(46.9) |
31 (47.7) |
Bilateral |
17(51.5) |
17(53.1) |
34(52.3) |
疾病过程 |
|
|
|
≥1 year <5 years before randomisation |
19 (57.6) |
18(56.2) |
37 (56.9) |
≥5 years before randomisation |
14(42.4) |
14 (43.8) |
28 (43.1) |
Previous treatment |
|
|
|
≥1 year <5 years before randomisation |
21 (66.7) |
22(68.7) |
38(67.7) |
≥5 years before randomisation |
11 (33.3) |
10(31.3) |
21 (32.3) |
敏感性测试结果阻力 |
|
|
|
Streptomycin |
30 (90.9) |
30(93.8) |
60(92.3) |
Isoniazid |
33(100) |
32(100) |
65(100) |
Rifampin |
33(100) |
32(100) |
65(100) |
Ethambutol |
29(87.9) |
30(93.8) |
59 (90.8) |
Ofloxacin |
33(100) |
32(100) |
65(100) |
Amikacin |
26 (78.8) |
25(78.1) |
51(78.5) |
Capreomycin |
25(75.8) |
25(78.1) |
50(76.9) |
背景方案 |
|
|
|
Prothionamide, pyrazinamide, moxifloxacin or gatifloxacin or levofloxacin, para-aminosalicylic acid |
33(100) |
32(100) |
65(100) |
Capreomycin or amikacin |
18(54.5) |
17(53.1) |
35(53.8) |
Clofazamine |
22 (66.7) |
20 (59.4) |
42(64.6) |
Clarithromycin |
18(54.5) |
19(51.5) |
37 (56.9) |